Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GSK3884464 in Healthy Participants
NCT05044325Phase 1Terminated
- Sponsor
- GSK
- Start
- Sep 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK3884464 in heart failure (HF) (5 cohorts), sponsored by GSK. Primary endpoints: Number of Participants With Adverse Events (AEs), Number of Participants With Worst Case Chemistry Results by Potential Clinical Importance (PCI) Criteria and 15 more. Started Sep 2021; status: terminated.
02
Drugs
GSK3884464
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT05044325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05044325.